US Patent

US8148333 — Stable composition comprising a PTHrP analogue

Formulation · Assigned to Ipsen Pharma SAS · Expires 2027-11-08 · 1y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable composition containing a parathyroid hormone-related protein (PTHrP) analogue for treating osteoporosis or increasing bone mass or quality.

USPTO Abstract

The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.

Drugs covered by this patent

Patent Metadata

Patent number
US8148333
Jurisdiction
US
Classification
Formulation
Expires
2027-11-08
Drug substance claim
No
Drug product claim
Yes
Assignee
Ipsen Pharma SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.